DOCUMENT
27/03/2024 East Region Formulary Committee Minutes
East Region Formulary ERFC Minutes 27 March 2024 Page 1 of 11 East Region Formulary Committee Minutes Date: 27 March 2024 Time: 2.00pm – 4.00pm Location: MS Teams Present: Carla Capaldi ...
Search Results
All Content Formulary Only Other ContentWe have found 12 results when searching "Etanercept"
FORMULARY DECISION
Etanercept : Enbrel
107/04 : Psoriatic arthritis
FORMULARY DECISION
Etanercept : Enbrel
TA383 (SMC 212/05) : For the treatment of severe active ankylosing spondylitis.
FORMULARY DECISION
Etanercept : Enbrel
TA383 (SMC 303/06) : For the treatment of ankylosing spondylitis.
FORMULARY DECISION
Etanercept : Enbrel
TA199 (SMC 304/06) : Psoriatic arthritis
FORMULARY DECISION
Etanercept : Enbrel
TA375 (SMC 305/06) : Rheumatoid Arthritis
FORMULARY DECISION
Etanercept : Enbrel
TA455 (SMC 570/09) : Chronic severe plaque psoriasis in children and adolescents
FORMULARY DECISION
Etanercept : Enbrel
TA455 (SMC 781/12) : For the treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years who are inadequately controlled by, or are intolerant to, other systemic t...
FORMULARY DECISION
Etanercept : Enbrel
TA373 (SMC 782/12) : For the treatment of active polyarticular juvenile idiopathic arthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have pro...
FORMULARY DECISION
Etanercept : Enbrel
842/13 : For the treatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents